<DOC>
	<DOCNO>NCT02166398</DOCNO>
	<brief_summary>A randomized , open-label , single dose , two-way crossover clinical trial compare safety , pharmacokinetic profile UI15AML055MT Amosartan® tablet 5/50 mg single oral administration healthy male volunteer</brief_summary>
	<brief_title>A Randomized , Open-label , Single Dose , Two-way Crossover Clinical Trial Compare Safety , Pharmacokinetic Profiles UI15AML055MT Amosartan® Tablet 5/50 mg After Single Oral Administration Healthy Male Volunteers</brief_title>
	<detailed_description>A randomized , open-label , single dose , two-way crossover clinical trial compare safety , pharmacokinetic profile UI15AML055MT Amosartan® tablet 5/50 mg single oral administration healthy male volunteer</detailed_description>
	<criteria>Patients 20 45 year age BMI state 19 27 mean sit SBP≥100mmHg mean sit DBP≥150mmHg screen mean sit SBP≥65mmHg mean sit DBP≥95mmHg screening Patients show clinically significant hematological finding , patient renal disease ( serum creatinine ) , patient hepatic disease ( ALT AST ) History alcohol drug abuse Positive pregnancy test , nurse mother , intention pregnancy Considered investigator appropriate participate clinical study othe reason</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Amlodipine basylate , Losartan potassium</keyword>
</DOC>